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ABSTRACT
MeCP2, whose methylated DNA-binding domain
(MBD) binds preferentially to DNA containing 5Me-
CpG relative to linear unmethylated DNA, also binds
preferentially, and with similar affinity, to unmethyl-
ated four-way DNA junctions through the MBD. The
Arg133Cys (R133C) mutation in the MBD, a Rett syn-
drome mutation that abolishes binding to methylated
DNA, leads to only a slight reduction in the affinity of
the MBD for four-way junctions, suggesting distinct
butpartiallyoverlappingmodesofbindingtojunction
and methylated DNA. Binding to unmethylated DNA
junctions is likely to involve a subset of the interac-
tions that occur with methylated DNA. High-affinity,
methylation-independent binding to four-way junc-
tions is consistent with additional roles for MeCP2
in chromatin, beyond recognition of 5Me-CpG.
INTRODUCTION
MeCP2 is an abundant vertebrate nuclear protein that binds
preferentially to a symmetrically methylated CpG dinuc-
leotide site in double-stranded DNA (1). It is abundant in
pericentric heterochromatin, which has a high concentration of
5Me-CpG, but is also present throughout chromosomal arms
(1). Two functional domains have been identiﬁed within
MeCP2 (human, 486 amino acid residues), each of  100
residues. A methyl binding domain (MBD) confers speciﬁcity
for methylated DNA (2) and has since been found in other
members of the MBD family of proteins (3); the solution
structures of the MBD of MeCP2 and of MBD1 have been
determined (4,5) and show a very similar fold. A transcrip-
tional repression domain (TRD) in MeCP2 (6) functions by
recruitment of the co-repressor Sin3A and a histone deacety-
lase (7,8). Other transcriptional co-repressors, such as Ski
and N-CoR, can also be recruited by MeCP2 and function
similarly (9). MeCP2 can thus mediate repression of transcrip-
tion through core histone deacetylation, which favours stable
andtranscriptionally inertchromatin,largelythrougheffectsat
the level of higher-order structure (30 nm ﬁlament). This could
provide a means of suppressing genome-wide transcriptional
‘noise’ (10) but also performs a critical role in repression at
speciﬁc loci such as imprinted genes [e.g. (11)], and pro-viral
(12) and other promoters, such as the brain-derived neuro-
trophic factor promoter (13,14). A third, less well-deﬁned,
domainthatspeciﬁes bindingtoGroupIIWWdomainsplicing
factors was mapped to the C-terminal region (residues 325–
486) of MeCP2 (15). Mutations in all three domains have been
found in Rett syndrome patients (InterRett-IRSA Phenotype
Database http://www.ichr.uwa.edu.au/rett/irsa/).
Histone deacetylase inhibitors such as trichostatin A do not
fully relieve the repressive effects of MeCP2 (8) suggesting
another, deacetylation-independent, pathway for MeCP2-
mediated repression (16,17). One possibility is that MeCP2
sequesters transcription factors or occludes their access to the
polymerase, but it is also clear that MeCP2 is able to bind to
unmethylated DNA in vitro, albeit with lower afﬁnity than to
methylated DNA [although only 2- to 3-fold fold lower in the
case of mouse MeCP2 binding to oligonucleotides, measured
by capillary electrophoresis (18)]. Another possibility, there-
fore, isthatMeCP2playsamethylation-independent structural
role in chromatin, e.g. in stabilizing a repressive structure such
as the 30 nm ﬁlament formed by folding of the 10 nm nuc-
leosome ﬁlament, or even more stable structures based on this.
Several (unrelated) observations support an uncoupling of
repression by MeCP2 from DNA methylation. First, the
chicken protein ARBP (attachment region binding protein),
believed to be the chicken MeCP2 homologue (19), interacts
preferentially in vitro with (unmethylated) nuclear matrix
attachment region DNA (20) as well as with (unmethylated)
chicken and mouse satellite DNA (19). A 25-residue sequence
containing an ‘AT-hook’ motif (-GRGRGRPK-) located
between the MBD and the TRD appears to be required
(19). Second, MeCP2 has been shown recently to condense
unmethylated, H1-deﬁcient, reconstituted nucleosomal arrays,
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doi:10.1093/nar/gki971which then self-associate to form ‘oligomeric chromatin
suprastructures’ (21). Third, the presence of MeCP2 and
dimethylation of H3K9 at a promoter are sufﬁcient to silence
it, in the absence of DNA methylation (22).
Methylation-independent MeCP2-mediated repression of
transcription from chromatin might occur by stabilization of
nucleosomes and/or chromatin compaction (21), in a function-
ally similar manner to stabilization by H1. The detailed mode
of interaction of H1 and MeCP2 might be different, although
there is circumstantial evidence that they may have overlap-
ping binding sites (6). H1 binds asymmetrically to the nucle-
osome, close to the dyad axis, contacting two DNA duplexes
through its globular domain (23,24). It also binds in a
structure-speciﬁc manner to four-way DNA junctions through
its globular domain (25–27), most probably because a pair of
junction arms mimics two juxtaposed duplexes in the
nucleosome. Here we investigate the binding of MeCP2
and its MBD to four-way junction DNA, and compare
this with binding to methylated DNA, as one approach
towards assessing the potential of MeCP2 to mediate effects
through chromatin-dependent, structure-speciﬁc, methylation-
independent interactions.
MATERIALS AND METHODS
Expression and purification of MeCP2 and its MBD
Plasmid pET17bMeCP2 (generated by D. Pate) contains the
rat MeCP2 cDNA sequence (2) cloned into the BamH1/EcoR1
sites of pET17b; the recombinant MeCP2 expressed from this
has an additional 20 amino acid residues (MASMTGGQQM-
GRDSSLVPSS) at its N-terminus, encoded by the vector.
pET6HMBD (28) is pET-3c with an insert encoding the
MBD (residues 78–164) of rat MeCP2; the MBD expressed
from this has an N-terminal His6 tag. Escherichia coli
BL21(DE3)pLysS cells transformed with plasmid pET17b-
MeCP2or pET6HMBD were grown at 37 Ci n2 · YT medium
to an OD600 ¼ 0.4–0.6 and expression of MeCP2 or the MBD
was induced with 0.5 mM isopropyl-b-D-thiogalactopyranos-
ide (IPTG) for 1 h. The cells were collected by centrifugation,
resuspended in buffer A (10 mM Tris–HCl, pH 7.5, 1 mM
EDTA, 1 M NaCl and 0.5 mM phenylmethylsulphonyl
ﬂuoride) containing protease inhibitors (100 mg/ml ben-
zamidine and 100 mg/ml 1-chloro-3-tosylamido-7-amino-L-
2-heptanone) and lysed with a French press. The supernatant
after centrifugation was diluted 10-fold in cold buffer B
(buffer A without 1 M NaCl), containing protease inhibitors
in the case of MeCP2, and applied to a S-Sepharose Fast Flow
(Fast S) FPLC column (Pharmacia) pre-equilibrated with buf-
fer B.Boundproteinswere eluted with agradientof 10column
volumes from buffer B to buffer A for MeCP2, and isocrat-
ically with buffer B alone for MBD, which binds much less
tightly.
In the case of MeCP2, the peak fractions were brought to
35% ammonium sulphate saturation at 4 C, and the supernat-
ant after centrifugation was applied to a PhenylSepharose
FPLC column (Pharmacia) equilibrated with buffer C (35%
saturated ammonium sulphate, 10 mM Tris–HCl, pH 7.5 and
1 mM EDTA). MeCP2 was eluted with a gradient from buffer
C to buffer B, dialyzed against buffer B, applied to a Resource
S column (Pharmacia) pre-equilibrated with buffer B, and
eluted with agradient from buffer BtobufferA.Peakfractions
were pooled, dialyzed against buffer B or 10 mM sodium
phosphate, pH 7.0, and stored at  80 C.
In the case of the MBD, the Fast S peak fractions were
pooled and applied to a Ni
2+–Sepharose Fast Flow column
(Sigma) pre-equilibrated with buffer A containing 20 mM
imidazole. The MBD was eluted with buffer A containing
300 mM imidazole, dialyzed against buffer B, and applied
to a Resource S column (Pharmacia) as described for MeCP2,
except that buffers also contained 3 mM dithiothreitol (DTT).
Fractions containing the MBD were dialyzed twice against
10 mM Tris–HCl, pH 7.5 and 3 mM DTT, and stored at
 80 C. The molecular mass was checked by MALDI-TOF
mass spectrometry and the protein concentration was calcu-
lated from the amino acid composition determined by auto-
mated analysis (both procedures carried out in the Protein and
Nucleic Acid Chemistry Facility, Department of Biochem-
istry, University of Cambridge).
Expression and purification of MBD R133C
The R133C mutation was introduced into pET6HMBD using
the Stratagene QuikChange kit according to the manufac-
turer’s instructions and veriﬁed by automated DNA sequen-
cing (DNA Sequencing Facility, Department of Biochemistry,
University of Cambridge). E.coli BL21(DE3) pLysS cells con-
tainingthe mutantMBD plasmid were grownat37 Cin2·YT
medium to an OD600 of 0.4–0.6, cooled to 23 C and induced
with 0.5 mM IPTG. After 5 h the cells were harvested and
lysed as for the MBD. The cleared, ﬁltered lysate was incub-
ated with Ni
2+–Sepharose 6B Fast Flow beads (Sigma) for 1 h
at4 C,and thebeads were washedwith buffer D(10mM Tris–
HCl, pH 7.5, 20 mM imidazole and 300 mM NaCl), and then
withbuffer E(10mM Tris–HCl, pH 7.5,75mM imidazoleand
300 mM NaCl). Bound proteins were eluted with 10 mM Tris–
HCl, pH 7.5 and 300 mM imidazole and dialyzed overnight
against 10 mM Tris–HCl, pH 7.5 and 75 mM NaCl. The
supernatant after centrifugation was applied to a Resource S
column (Pharmacia) pre-equilibrated with 10 mM Tris–HCl,
pH 7.5, 75 mM NaCl. MBD(R133C) was eluted with a linear
gradientfrom75mMto1MNaClin10mMTris–HCl,pH7.5,
dialyzed twice against 10 mM Tris–HCl, pH 7.5 or 10 mM
sodium phosphate, pH 7.0, and stored at  80 C. The molecu-
lar mass and protein concentration were determined as
described above.
Gel-retardation assays
Gel-retardation assays were carried out with three
32P-end-
labelled probes: two 17 bp oligonucleotides formed by anneal-
ing 50-CAGTGCGACACGGCATGCCTG-30 and its comple-
mentary strand, with the central CpG (bold) either methylated
or not on both strands, and a
32P-end-labelled four-way DNA
junction with 15 bp arms formed by annealing four synthetic
30mer oligonucleotides (29), all of which were 50-end-
labelled. Binding of MeCP2 and the MBD to
32P-labelled
DNA was carried out in 10 ml of 10 mM Tris–HCl, pH 7.5,
150 mg/ml BSA, 0.1% Nonidet-P40, 3 mM DTT, 5% glycerol
and 50 or 125 mM NaCl, as speciﬁed, for MBD, or 150 mM
NaCl for MeCP2, with or without unlabelled 17 bp oligonuc-
leotide (methylated or not as speciﬁed) or sonicated E.coli
DNA (Sigma) as competitors. The DNA ( 0.27 nM; added
6604 Nucleic Acids Research, 2005, Vol. 33, No. 20last, with competitor where applicable) was incubated with
increasing concentrations of protein for 30 min at room tem-
perature (incubation at 37 C did not affect the results; data
not shown) and loaded on to 6.5 or 7% polyacrylamide gels
containing 0.5· TB (45 mM Tris and 45 mM boric acid),
which were run at 150 V at room temperature. Gels were
vacuum-dried and exposed overnight at  80 C to pre-
ﬂashed X-ray ﬁlm.
RESULTS
MeCP2 interacts with four-way junction DNA,
through its MBD
The ability of recombinant rat MeCP2 and the isolated MBD
to interact with (unmethylated)
32P-labelled four-way junction
DNA was investigated in gel-retardation assays. With MeCP2
a complex was ﬁrst apparent at 5 nM protein (Figure 1A, lane
4); the apparent Kd for the interaction (in 150 mM NaCl) is 20–
40 nM (lanes 6 and 7). The MBD (Figure 1B) behaved very
similarly, with an apparent Kd (in 125 mM NaCl) of 20–40 nM
(lanes 5 and 6). The lower mobility bands observed at the two
highest protein concentrations in the absence of competitor are
most probably owing to weaker, non-structure-speciﬁc bind-
ing of MBD and MeCP2 to additional sites on the junction
arms. The H1 and H5 globular domains, and HMGB1, which
bindtoapairofjuxtaposedarmsandthecross-overinthe four-
way junction, respectively, show similar secondary binding
(27,30,31). A 75-fold molar excess of sheared E.coli DNA
reduced binding of both MeCP2 (compare Figure 1A, lanes
7 and 8, with Figure 1C, lanes 3 and 4) and the MBD (compare
Figure 1B, lanes 7 and 8, with Figure 1D, lanes 3 and 4) by
roughly 50%, but even in the presence of a 225-fold molar
excessofcompetitor(Figure1CandD,lanes9and10)binding
was not abolished. The very similar behaviour of MeCP2 and
its MBD (Figure 1A–D) suggests that the interaction of
MeCP2 with four-way junction DNA is mediated through
high-afﬁnity binding of the MBD, with little contribution
from other regions of the protein.
In gel-shift assays with a 17 bp singly methylated duplex,
there was a single complex; the Kd was 10–20 nM in 125 mM
NaCl (Figure 2A), similar to that of the MBD for four-way
junctions under the same conditions ( 20–40 nM; Figure 1B).
No additional lower mobility bands were observed at the
higher protein concentrations in this case, further suggesting
that the additional bands with four-way junctions are due to
protein–DNA interactions with the junction arms, rather than
protein–protein interactions between added and bound MBD
[which, like MeCP2 (32), is monomeric when free in solution
(data not shown)]. MBD binds to the corresponding unmethyl-
ated 17 bp duplex under the same conditions with much lower
afﬁnity, as expected, and the complexes are much less stable
(data not shown). The DNA-binding properties of the MBD
were further investigated by comparing its ability to bind
32P-
labelled 17 bp DNA (both methylated and unmethylated) and
four-way junction DNA in the presence of a 30-fold molar
excess of 17 bp competitor DNA that was either unmethylated
(Figure 2B–D, lanes 2–7) or methylated (lanes 8–13). Only the
methylated competitor competed effectively for binding of the
MBD to the radiolabelled methylated 17 bp DNA (Figure 2B)
or to the four-way junction (Figure 2D), but even in the pres-
ence of the competitor strong binding persisted at the higher
concentrations of MBD (80 nM and above). The weaker bind-
ing to the unmethylated probe was completely abolished when
the competitor was methylated (Figure 2C) and largely abol-
ished even by unmethylated competitor. Thus the MBD of
Figure 1. Binding of MeCP2 and its MBD to four-way junction DNA.
32P-labelled four-way junction DNA ( 0.27 nM) was incubated with increasing amounts of
MeCP2(AandC) orMBD(B andD) intheabsence(A andB)orpresence(CandD) ofE.colicompetitorDNAin 75-,150-or225-foldmolarexcessoverfour-way
junctionDNA.Theincubationscontained150mMNaCl(MeCP2)or125mMNaCl(MBD).Sampleswereanalysedin6%(MeCP2)or7.5%(MBD)polyacrylamide
gels; autoradiographs are shown [of the whole gel in (A and C); of the portions showing bands in (B and D)].
Nucleic Acids Research, 2005, Vol. 33, No. 20 6605MeCP2 interacts structure-speciﬁcally with (unmethylated)
four-way junction DNA in conditions in which it does not
bind to unmethylated linear DNA, and it binds four-way
junction DNA with 15 bp arms and singly methylated DNA
of 17 bp with similar afﬁnity.
Overlapping binding sites for methylated and four-way
junction DNA
The Rett syndrome mutation R133C in MeCP2 disrupts bind-
ing of the MBD to methylated DNA in vitro (33–35). To test
whether there was overlap between the interactions involved
in methyl CpG-dependent binding of the MBD to linear DNA
and structure-speciﬁc binding to four-way junctions, binding
of the R133C MBD mutant to four-way junction DNA and
methylated DNA was compared (Figure 3). The afﬁnity of the
R133C mutant was only slightly lower ( 2-fold) than that of
wild-type MBD (Figure 3A). In contrast, binding to singly
methylated 17 bp DNA was severely impaired and in the
presence of a 20-fold excess of 17 bp methylated DNA was
abolished (Figure 3B); there was no binding to unmethylated
17 bp DNA (data not shown). The binding site for interaction
of the MBD with methylated duplex DNA must thus be largely
distinct from the binding site(s) for four-way junctions, but
there might be some overlap between the sites. Virtually ident-
ical near-UV CD spectra for the wild-type MBD and the
R133C mutant (data not shown) indicate that the differences
in methylated DNA binding are not a result of any signiﬁcant
conformational change introduced by the mutation, as indic-
ated also by NMR spectroscopy (34).
DISCUSSION
The main conclusion from the results reported here is that
MeCP2, as well as its isolated MBD, binds to four-way junc-
tion DNA in a structure-speciﬁc, methyl-CpG-independent
manner. The afﬁnity for the junction is similar to that for
methylated DNA (Figures 1B and 2A). Double-stranded com-
petitor DNA, whether methylated or unmethylated, had only a
small effect on junction binding (Figure 2D) but abolished
binding to the unmethylated probe (Figure 2C), showing
that the interaction with four-way junction DNA is speciﬁc.
Mutation of a methyl-CpG binding residue [R133C, a Rett
syndrome mutation that essentially abolishes binding to
methylated DNA (33–35); Figure 3B] reduces binding to
four-way junction DNA by only  2-fold (Figure 3A), sug-
gesting largely distinct, but possibly overlapping, binding sites
for the two DNA substrates. Formation of MeCP2-dependent
‘oligomeric chromatin suprastructures’ in vitro from reconsti-
tuted unmethylated nucleosomal arrays, like four-way junc-
tion binding, also appears not to be affected by the R133C
mutation inMeCP2 (21).In other words, MeCP2 has a methyl-
CpG-dependent binding mode and a methylation-independent
chromatin binding mode which, in an array of MeCP2-
containing nucleosomes, leads to chromatin condensation.
Certain features of chromatin binding may be reﬂected in
binding of MeCP2 to four-way junctions.
MeCP2 forms ‘tramline’ complexes with long DNA (21).
Complexes of this type have been demonstrated previously for
the linker histones H1 and H5 and their isolated globular
domains (36,37)and inthose cases, likebindingof the proteins
to the juxtaposed duplexes of four-way junctions (27), are
taken to reﬂect the existence of two DNA-binding sites on
opposite faces of the globular domain (38); the existence of
two sites was supported by mutagenesis studies (25,39). In the
nucleosome the two binding sites engage with two duplexes in
the general vicinity of the dyad axis (24). Since MeCP2, like
H1 and H5, assembles linear DNA into tramlines and binds
selectively to four-way junctions, it seems possible that it, too,
might bind two DNA duplexes, perhaps (but not necessarily)
binding similarly to H1 and H5. However, if MeCP2 does
contact two DNA strands, it remains to be determined whether
the two binding sites are on the MBD, since the ability of the
MBD to form tramlines was not reported (21).
The detailed mode of binding of MeCP2 to DNA and chro-
matin remains to be investigated. There is circumstantial evid-
ence suggesting that MeCP2 and H1 may have overlapping
binding sites in chromatin. Addition of MeCP2 to methylated
plasmid DNA that had been assembled into chromatin in a
Xenopus oocyte extract and reconstituted with H1 displaced
some (40%) of the bound H1 (6), although if the nucleosome
+ unmeth. comp. + meth. comp.
C
D
123 456 9 7 8 10 11 12 13
17 bp 
unmeth.
4WJ 4WJ
Cx
B
(nM MBD) 01 0 2 0 40 80 160 0 10 20 40 80 160 5
17 bp meth.
0 10 20 40 80 160 320
1 2 3 456 7
A
17 bp 
meth.
(nM MBD)
Figure 2. Comparison of the binding of the MBD of MeCP2 to methylated
DNA and four-way junctions. (A) Binding to methylated duplex DNA (no
competitor DNA).
32P-labelled methylated 17 bp DNA duplex ( 0.27 nM)
was incubated with increasing concentrations of MBD in the presence of 125
mMNaClandthesampleswereanalysedby6.5%PAGEandautoradiography.
(B–D) Binding of the MBD of MeCP2 to methylated DNA and four-way
junction DNA in the presence of competitor. (B)
32P-labelled singly methy-
lated, (C) unmethylated 17 bp duplex or (D) four-way junction DNA (all
 0.27 nM) was incubated with increasing concentrations of MBD. Reactions
contained a 30-fold molar excess of unlabelled 17 bp duplex DNA that was
either unmethylated (lanes 2–7) or methylated (lanes 8–13) as competitor and
50 mM NaCl. Samples were analysed by 7.5% PAGE and autoradiography.
Cx indicates the first protein–DNA complex with the four-way junction.
6606 Nucleic Acids Research, 2005, Vol. 33, No. 20occupancy of the DNA was not complete, it is possible that the
displaced H1 was bound not to nucleosomes but to stretches of
naked DNA.However,ifMeCP2doesbindat,orinsuchaway
that it overlaps, a linker histone binding site, in contrast to H1
binding (40) it does not lead to protection of chromatosomes
(containing 166 bp DNA) in vitro during micrococcal nuclease
digestion (A. Sanderson and J. O. Thomas, unpublished data).
It does confer protection from DNase I digestion on a methyl-
ated CpG at the dyad axis of a nucleosome assembled on
methylated 5S rDNA (41), but this is presumably due to
methylation-dependent binding rather than structure-speciﬁc
recognition, since there was no protection against DNase I
digestion when the DNA was not methylated. Moreover, des-
pite tramline formation by MeCP2 it remains possible that the
feature in four-way junctions that is recognized by MeCP2 and
its MBD is not a pair of juxtaposed duplexes per se, but the
distortion at the cross-over of the duplexes where bases are
unstacked, e.g. as is the case for HMGB1 (29,42).
What mightbe thebasis oftheinteraction of theMBD of
MeCP2 with unmethylated DNA?
Molecular details of the interaction of the highly homologous
(46% identical) MBD of MBD1 with methylated DNA are
known from an NMR structure of the complex (43); similar
interactions are inferred for the MBD of MeCP2, based on
chemical shift changes in the protein on binding to methylated
DNA (34). The MBD in both MeCP2 (5) and MBD1 (4) is a
wedge-shaped a/b sandwich, with a C-terminal a-helix. In the
complex of the MBD (of MBD1) with methylated DNA, the
anti-parallel three-stranded b-sheet ﬁts into the major groove
(43). The buried interface is relatively small (810 s
2) (43),
consistent with the ability of MeCP2 to bind to methylated
nucleosomal DNA without nucleosomal disruption (41).
Recognition of the two methyl CpGs takes place, asymmet-
rically, through hydrophobic and polar interactions in a pocket
formed by six residues in b-strands 2 and 3 (b2 and b3) and
loops 1 and 2 (L1 and L2). These residues are Val20 (in b2),
Arg22 (L1), Asp32 (b3), Tyr34 (b3), Arg44 (L2) and Ser45
(L2). In addition there are extensive contacts with the sugar-
phosphate backbone, including phosphate contacts with
arginine or lysine residues in loops L1 and L2 and with the
N-terminus of helix a1. Most of the residues involved in
MBD1 are conserved in MeCP2. A subset of the interactions,
e.g. involving the phosphates and sugars but possibly also
those involving residues in the pocket that normally binds
5Me-CpG, is likely to account for the binding of MeCP2 to
non-methylated DNA. However, the higher-afﬁnity preferen-
tial binding to four-way DNA junctions relative to unmethyl-
ated linear DNA implies additional, structure-speciﬁc
interactions with junction DNA (and possibly the ability to
satisfy two DNA-binding sites intramolecularly), the nature of
which is not yet clear.
There are three unrelated b-sheet proteins/domains with a
C-terminal a-helix that exhibit conserved features of DNA
binding to the major groove of (unmethylated) DNA (44):
the I-PpoI homing endonuclease (45), the DNA-binding
domain of the Tn916 integrase [Tn916Int (46)], and the
DNA-binding domain of the GCC-box binding protein
AtERF1 (47). In these cases the b-sheet lies ﬂat in the major
Figure 3. EffectoftheRettmutationR133ConbindingoftheMBDofMeCP2tofour-wayjunctionDNAandmethylatedDNA.(A)
32P-labelledfour-wayjunction
DNA( 0.27nM)wasincubatedwithincreasingamountsofwild-typeorR133CmutantMBDasindicated.(B)
32P-labelled17bpmethylatedDNA( 0.27nM)was
incubatedwithincreasingamountsofR133CmutantMBDintheabsence(left)orpresence(right)ofa20-foldexcessofunlabelled17bpsinglymethylatedDNA.All
samples(AandB)contained125mMNaClandwereanalysedby6.5%PAGEandautoradiography.Cxindicatesthepositionofthefirstprotein–DNAcomplexwith
the four-way junction.
Nucleic Acids Research, 2005, Vol. 33, No. 20 6607groove, rather than being twisted as in the MBD of MBD1, as
noted (43). Although the proteins have no overall sequence
homology there are striking similarities between the MBD1
contacts with methylated DNA and the Tn916Int contacts with
unmethylated DNA.Key protein–DNA contacts involve ident-
ical or similar amino acids at corresponding positions in the
b-sheets and loops (Figure 4; see legend for details). We
suggest that similar considerations are likely to apply to the
binding of the MBD of MeCP2 (Figure 4, top line) to
unmethylated DNA. The similarities in key residues between
the methylated-DNA-binding MBD1 and the other proteins,
whose DNA-bindingsites are not methylated, suggests that the
MBD of MeCP2 (and presumably of MBD1) could interact
with unmethylated DNA using a subset of the contacts used to
bind to methylated DNA.
Whatever the details of the interaction of the MBD of
MeCP2 with four-way junction DNA, it represents high-
afﬁnity, methylation-independent binding to a DNA structure
that is accepted as mimicking certain features of DNA archi-
tecture around the dyad axis of the nucleosome. This mode of
binding may be related to the ability of MeCP2 to condense
extended arrays of unmethylated nucleosomes (21). Further
investigation of the interaction of MeCP2 with unmethylated
DNA and chromatin is in progress in order to deﬁne any direct
role it may play in chromatin structure and function.
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